CMU Taiwan hosts exosome therapeutics forum, with keynote by Nobel Laureate
CMU Taiwan hosts exosome therapeutics forum, with keynote by Nobel Laureate
2025-06-24
China Medical University in Taichung has a leading development in next-generation applications of extracellular vesicles, or EVs in treating various diseases, including cancers. On Tuesday, the university held a forum, with leading researchers from the US and Taiwan taking part. The keynote speaker was Dr. Randy Schekman, who won the Nobel Prize in 2013. Dr. Sheckman was also announced as the R&D consultant for the university’s research project in developing the SOB100 EV platform.
Members of the audience appear fully concentrated in hearing the presentation. This high-level forum is being held at China Medical University’s Shuinan Campus. Experts from Taiwan and the US, including research scientists, clinical experts and biotechnology industry leaders are here to discuss novel therapeutic applications of extracellular vesicles, or EVs, particularly exosomes, in treating cancer and neurodegenerative diseases through immunoregulation.
Randy W. Schekman
Nobel Laureate
In our body, exosomes are produced from all of the tissues in our body. They’re a kind of little reporters of what’s going on in the body. So I think that’s gonna be their most useful, beneficial application. And then just being able to isolate them and characterize them is basic science is going to provide biotechnology with tools they need to interrogate.
The leading authority at the forum is none other than Dr. Randy Schekman, a winner of the 2013 Nobel Prize in Physiology or Medicine. He’s also the research and development consultant for the university’s and a biomedical company’s joint venture in next-generation EV therapeutics, elevating the initiative to the international stage.
Cho Der-yang
China Medical University Hospital superintendent
They’re not only used in treating cancer, but also have promising applications in severe conditions, such as dementia and Parkinson’s disease. EVs can even possibly change the course of treatment altogether, so they really have great potential in the future.
The project aims to develop HLA-G targeting exosomes called SOB100. After extensive development, SOB100 has been approved by the US FDA and has began Phase One clinical trials. Of course, there were challenges to overcome.
Ho Hui-chun
Shine-on Biomedical Co. VP
A great challenge for the production process that’s inherent to EVs was that unlike cells, EVs cannot stay active under frozen conditions. How to prolong their shelf life as a drug, if you will, was a considerable challenge to overcome in terms of production.
Researchers at leading institutions in Taiwan, such as National Health Research Institutes and Academia Sinica also presented at the forum, driving the development of cutting-edge EV precision therapeutics in the country.
For more Taiwan news, tune in:
Mon to Fri at 9:30 pm on Channel 152
Tue to Sat at 1 am on Channel 53
#healthcare #cancertreatment #parkinsons #neurology #biotechnology #nobelprize
中醫大引領"外泌體精準醫療" 諾貝爾獎得主任國際顧問
2025-06-24
台中市中國醫藥大學附設醫院，引領外泌體精準醫療邁向國際，今日隆重在水湳校區舉辦國際論壇，探討外囊泡在各領域的創新應用，而論壇中也正式宣布，邀請2013年諾貝爾生理醫學獎得主，擔任外泌體研發國際顧問。
講堂內，座無虛席，所有聽眾全神貫注，沈浸在論壇中，台中中國醫藥大學附設醫院，隆重在水湳校區，舉辦一場重量級論壇，邀請美國及台灣頂尖科學家，臨床專家，以及生醫產業領袖，深入探討外囊泡，對於癌症，神經退化等領域的免疫調控創新應用。
[[2013年諾貝爾生理醫學奬得主 Randy.W.Schekman]]
“在我們人體，各種有生命的細胞都會有外泌體，它們就像記者，讓你知道身體發生什麼事。我認為如果我們可以透過外泌體這樣的診斷工具，會是最有效的 的一種運用方式，只要我們可以把它單獨出來，對於基本科學會有非常大的幫助”
而論壇最大亮點，便是院方及生醫公司，宣布邀請2013年諾貝爾生理醫學獎得主Randy.W.Schekman，擔任外泌體研發國際顧問，正式與國際接軌。
[[中國醫藥大學附設醫院院長 周德陽]]
“它不是只有在做癌症，它其實對現在最嚴重的像失智症、帕金森病，它可以用它的方法減少，甚至可以改變治療過程，所以它的未來的潛力非常的大”
而三方合作的研發核心項目，也就是SOB100外泌體平臺，經過長時間規劃，推行，成功通過，美國FDA核准，進入第一期臨床試驗，當然期間，也遇到種種挑戰。
[[生醫公司副總經理 何慧君]]
“外泌體它其實本身就是一個很不容易克服，在生產製程上面很不容易克服的技術，其實它不像是細胞一樣，它可以在冷凍的環境底下活得很久。怎樣能夠延長它在這個作為藥物的有效期，所以這個也是一個在生產製程上面，非常難突破的地方”
此次論壇，集合了全台灣細胞外囊泡領域的學術重鎮，包括國衛院，中研院等研究機構的學者皆一同到場參與論壇，多方合作，也為台灣外泌體精準醫療，注入強大動能。
更多新聞內容，請鎖定：
民視台灣台（152頻道）週一至週五晚上9:30
民視新聞台（53頻道）週二至週六凌晨1:00
Related News
